Hernia repair, breast reconstruction and sling devices containing poly(butylene succinate)

USPTO granted patent US12594361B2 to Tepha, Inc. on April 7, 2026, covering resorbable implants made from poly(butylene succinate) and copolymers for hernia repair, breast reconstruction, and sling devices. The patent includes 17 claims and covers sterilized devices with specific endotoxin requirements, oriented fibers, meshes, and 3D-printed forms. The technology also includes receptacles for cardiac rhythm management devices such as pacemakers and neurostimulators.

Orthotic and Prosthetic Device and Manufacturing System and Method

USPTO granted patent US12594173B2 to Hanger, Inc. for an orthotic and prosthetic device including a socket, fasteners, and pylon system. The patent covers the mechanical coupling design between socket components and pylon through threaded fasteners extending through aligned through-holes and blind-holes. This patent affects medical device manufacturers developing prosthetic limbs.

Vasopressin-2 receptor antagonist peptides and uses thereof

The USPTO has granted Patent US12595288B2 to Commissariat à l'Énergie Atomique et aux Énergies Alternatives covering vasopressin-2 receptor antagonist peptides. The patent protects peptide sequences with at least 80% amino acid identity to SEQ ID NO. 1, with specific modifications at variable positions enabling therapeutic applications. The grant includes 14 claims.

Methods to Decrease Impurities from Recombinant Protein Manufacturing Processes

The USPTO granted Patent US12595294B2 to Hoffmann-La Roche Inc. on April 7, 2026. The patent covers methods for reducing non-aggregate produce-related impurities (NAPRIs) in buffered solutions of monoclonal antibodies using synthetic depth filters. Inventors are Marc Pompiati and Christoph Feistl, with 15 claims in the granted patent.

Anti-NGF Antibody and Antigen-Binding Fragment Patent Grant

USPTO granted Patent US12595298B2 to XIYUAN ANJIAN MEDICINE (SHANGHAI) CO., LTD. for an anti-NGF antibody and its antigen-binding fragment, covering the preparation method and therapeutic applications for NGF-mediated diseases. The patent includes 6 claims and was filed on August 2, 2021.

Fc Variants and IL-8 Antibodies Patent Grant

USPTO granted patent US12595299B2 to Chugai Seiyaku Kabushiki Kaisha covering Fc region variants with improved antigen binding in ion concentration-dependent manner, Fc variants with decreased binding to pre-existing anti-drug antibodies, and novel IL-8 antibodies for pharmaceutical use. The patent contains 17 claims and covers molecules derived from antibody engineering technology.

Anti-human P40 protein domain antibody and use thereof

USPTO granted Patent US12595300B2 to Akeso Biopharma, Inc. covering an anti-human P40 protein domain antibody for treating autoimmune diseases. The patent includes 20 claims with specific amino acid sequences for heavy and light chain variable regions (SEQ ID NOs 1, 24 for heavy chain; SEQ ID NOs 6, 11, 13, 15, 17, 25 for light chain).

LMP-1 Expressing Cells and Methods of Use Thereof - Dana-Farber Cancer Institute

Dana-Farber Cancer Institute, Inc. has been granted USPTO Patent US12595285B2 covering immunogenic cells expressing LMP1 and methods of use for cancer treatment and T cell activation. The patent, with 15 claims, names Baochun Zhang, Il-Kyu Choi, and Zhe Wang as inventors, with an application filing date of May 13, 2022.

P2X3 receptor antagonist patent, Beijing Tide Pharma, 6 claims

P2X3 receptor antagonist patent, Beijing Tide Pharma, 6 claims

Heterocyclic GLP-1 agonists

USPTO granted patent US12595264B2 to Gasherbrum Bio, Inc. on April 7, 2026, covering heterocyclic GLP-1 receptor agonists of Formula (I), including pharmaceutical salts, solvates, and compositions. The patent names six inventors and contains 24 claims, with CPC classifications spanning heterocyclic chemistry (C07D 487/04), phosphorus compounds (C07F 9/6561), and pharmaceutical formulations (A61K 31/4985, A61K 38/26).